This study will collect safety information during routine medical care for children and adolescents in Japan who have been diagnosed with NTRK fusion-positive advanced or recurrent solid tumors who start treatment with repotrectinib. The study will describe how often side effects occur during treatment, with special attention to central nervous system disorders, interstitial lung disease, and fractures.
Age range
4 Years – 17 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of participants with 1 or more adverse events (AEs)
Timeframe: Up to week 104
Number of participants with 1 or more serious adverse events (SAEs)
Timeframe: Up to week 104
Number of participants with adverse events by system organ class (including central nervous system disorders, interstitial lung disease, and fractures)
Timeframe: Up to week 104
Number of participants with adverse events (AEs) leading to treatment modification (interruption, dose reduction, or discontinuation)
Timeframe: Up to week 104
Number of participants with each adverse event outcome category (resolved, resolving, not resolved, resolved with sequelae, death, unknown)
Timeframe: Up to week 104
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com